News Chart Kalytera Therapeutics Inc Toronto S.E.

Equities

End-of-day quote Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^PTS	-.--%		-.--%	-.--%

2021	Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	MT
2021	Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	CI

7.wB_UbaRiEd9KgAtQ3rqUUY4MMrdL0iPsqTMFwUwKSaw.sVCEC9BQJuk-4z0Aqf37Acs_QuEIlhuUnHp9ph1Ve5SPQOBe4zAi6hvqWg~83beb0a367ba893c8e19f283411c61d2